Kornhuber J, Weller M.
Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
Biol Psychiatry. 1997 Jan 15;41(2):135-44.
PubMed.
This is a review article that addresses an important topic and provides reasonably accurate information, but the authors have a hidden bias that decreases the value of the article. These authors are academically oriented but they are closely affiliated with a German pharmaceutical firm that manufactures memantine, the drug that they are claiming is the preferred NMDA antagonist for neurotherapeutic purposes in a wide range of human neurological disorders. In fact, memantine is not a very powerful NMDA antagonist and is not likely to be effective as a neuroprotective agent unless used in very high doses and high doses will entail psychotic and neurotoxic side effects
Comments
This is a review article that addresses an important topic and provides reasonably accurate information, but the authors have a hidden bias that decreases the value of the article. These authors are academically oriented but they are closely affiliated with a German pharmaceutical firm that manufactures memantine, the drug that they are claiming is the preferred NMDA antagonist for neurotherapeutic purposes in a wide range of human neurological disorders. In fact, memantine is not a very powerful NMDA antagonist and is not likely to be effective as a neuroprotective agent unless used in very high doses and high doses will entail psychotic and neurotoxic side effects
Make a Comment
To make a comment you must login or register.